Equities

Silo Pharma Inc

SILO:NAQ

Silo Pharma Inc

Actions
Consumer DiscretionaryConsumer Discretionary
  • Price (USD)1.28
  • Today's Change0.00 / 0.00%
  • Shares traded163.45k
  • 1 Year change-17.42%
  • Beta1.5166
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

  • Revenue in USD (TTM)72.12k
  • Net income in USD-3.45m
  • Incorporated2012
  • Employees3.00
  • Location
    Silo Pharma Inc677 N. Washington BlvdSARASOTA 34236United StatesUSA
  • Phone+1 (718) 400-9031
  • Websitehttps://silopharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shuttle Pharmaceuticals Holdings Inc0.00-7.20m3.88m8.00--3.05-----10.29-10.290.000.38050.00----0.00-123.53---147.27-------------4.320.5076-------112.71------
CYANOTECH CORP23.82m-5.10m4.14m77.00--0.3878--0.1738-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
Evoke Pharma Inc7.53m-6.53m4.15m4.00--1.56--0.5517-16.23-16.2311.243.630.71280.43074.971,881,428.00-61.83-100.48-136.53-151.1096.97---86.75-480.521.22-19.910.6523--106.51--5.25------
Tian'an Pharmaceutical Co Ltd10.65m3.14m4.16m--0.02320.0051.140.39060.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Biofrontera Inc35.24m-13.51m4.75m85.00--0.3997--0.1347-5.29-5.2912.122.141.211.977.27414,623.50-46.20---113.24--47.75---38.33--1.46-3.530.0264--18.82---3,045.47------
Sunshine Biopharma Inc30.48m-3.68m5.38m44.00--0.1341--0.1765-194.01-194.011,017.8520.071.063.3310.19692,772.50-12.75-101.52-15.41-137.0430.4135.47-12.07-165.333.26--0.00--454.42--83.15--110.99--
Aoxing Pharmaceutical Company Inc30.11m-1.46m5.46m339.00--0.0638--0.1813-0.0192-0.01920.39510.25070.4962.322.56---2.41-14.54-7.06-35.4576.1968.51-4.85-37.690.73680.33870.6052--26.8837.20-62.49---38.80--
AgriFORCE Growing Systems Ltd57.60k-15.05m5.53m7.00--0.3508--95.95-5.81-5.810.00370.13430.0034--1.218,228.57-88.79-78.95-124.14-109.8617.86---26,121.49-243,182.501.24-1.280.0789------8.85--48.61--
Bon Natural Life Ltd25.56m2.47m5.60m96.000.53790.05431.490.21912.622.6222.9525.950.525411.402.94266,207.704.9514.046.5920.6827.7530.009.4217.622.3216.880.14380.00-1.2922.32-26.3283.09-6.70--
Sentient Brands Holdings Inc0.00-954.07k5.65m2.00---------0.0164-0.01640.00-0.03070.000.00--0.00-460.67-220.36------41.81---31,451.190.0015-2.50-----73.68--34.98------
Silo Pharma Inc72.12k-3.45m5.74m3.00--0.7994--79.59-1.16-1.180.02421.600.0079----24,040.00-37.69-24.90-43.50-26.3991.9082.79-4,777.02-2,757.85----0.00--0.00--7.07------
Hoth Therapeutics Inc0.00-7.46m6.34m2.00--0.5267-----1.69-1.690.001.740.00----0.00-67.99-157.07-76.33-177.32------------0.00------31.01------
Healthy Extracts Inc2.88m-1.37m6.75m----16.88--2.35-0.4725-0.47250.98450.13361.120.665428.03---53.40-53.78-168.81-146.6567.8345.68-47.73-87.530.2059-0.91530.7131--10.41105.93-151.54------
GT Biopharma Inc0.00-11.35m7.44m2.00--1.35-----7.72-7.720.002.470.00----0.00-82.84-205.36-120.73--------------0.00------63.62------
Data as of Nov 08 2024. Currency figures normalised to Silo Pharma Inc's reporting currency: US Dollar USD

Institutional shareholders

2.13%Per cent of shares held by top holders
HolderShares% Held
Virtu Americas LLCas of 30 Jun 202441.85k0.93%
The Vanguard Group, Inc.as of 30 Jun 202416.33k0.36%
Geode Capital Management LLCas of 30 Jun 202416.18k0.36%
SSgA Funds Management, Inc.as of 30 Jun 202412.50k0.28%
Tower Research Capital LLCas of 30 Jun 20246.66k0.15%
Redwood Wealth Management Group LLCas of 30 Jun 20242.00k0.05%
Westside Investment Management LLCas of 30 Jun 202494.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 202417.000.00%
JPMorgan Securities LLC (Investment Management)as of 30 Sep 20241.000.00%
Financial Advocates Investment Management LLCas of 30 Sep 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.